ITOS vs. RXRX

Last updated Apr 1, 2026

Compare and contrast key facts about iTeos Therapeutics, Inc. (ITOS) and Recursion Pharmaceuticals, Inc. (RXRX).

Performance

ITOS vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iTeos Therapeutics, Inc. (ITOS) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

ITOS vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ITOS iTeos Therapeutics, Inc.	0.00%	32.16%	-29.86%	-43.93%	-58.05%	108.88%
RXRX Recursion Pharmaceuticals, Inc.	-24.94%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%

Fundamentals

Market Cap ITOS : $442.18M RXRX : $1.62B
EPS ITOS : -$4.65 RXRX : -$1.39
PB Ratio ITOS : 0.90 RXRX : 1.43
Total Revenue (TTM) ITOS : $0.00 RXRX : $74.56M
Gross Profit (TTM) ITOS : -$35.01M RXRX : $3.73M
EBITDA (TTM) ITOS : -$195.33M RXRX : -$579.69M

Returns By Period

ITOS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

RXRX

• 1D: 8.10%
• 1M: -16.35%
• YTD: -24.94%
• 6M: -37.09%
• 1Y: -41.97%
• 3Y*: -22.79%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ITOS vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXRX

RXRX Risk / Return Rank: 17
RXRX Sharpe Ratio Rank: 20
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 13
RXRX Martin Ratio Rank: 7

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ITOS vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iTeos Therapeutics, Inc. (ITOS) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	ITOS	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.50	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.40	—

Correlation

The correlation between ITOS and RXRX is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ITOS vs. RXRX - Dividend Comparison

Neither ITOS nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

Drawdown Indicators

	ITOS	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	—	-93.13%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-58.17%	—
Current Drawdown Current decline from peak	—	-92.57%	—
Average Drawdown Average peak-to-trough decline	—	-74.76%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	29.28%	—

Volatility

Volatility by Period

	ITOS	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	14.77%	—
Volatility (6M) Calculated over the trailing 6-month period	—	54.53%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	84.44%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	94.56%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	94.56%	—

Financials